AANOX — From Amino Acids to Approved Therapeutics
AANOX Ltd (London, UK · Delaware, USA) provides the unified causal intelligence operating substrate spanning first-principles molecular discovery, CMC formulation digital twins, and GxP-audited clinical development.
What Makes AANOX Different: Causal vs. Correlational AI
Legacy machine learning models identify surface statistical patterns, leading to 90% clinical attrition. AANOX is built on Structural Causal Models (SCMs) and do-calculus interventional reasoning to distinguish genuine causal disease drivers from passenger biomarkers.
The Five Enterprise Solution Clusters
- Upstream Discovery & Validation — Interventional target identification, causal genetic perturbation, quantum-classical binding affinity, multi-objective ADMET lead optimization.
- CMC & Formulation Digital Twins — Unit operation digital twins, accelerated stability forecasting, automated regulatory dossier generation with batch traceability.
- Downstream Clinical Command Center — Precision multimodal patient matching, real-time Bayesian adaptive trial updating, causal adverse event attribution.
- Hospital & Precision Care Intelligence — FDA-aligned white-box reasoning above EHRs for clinical deterioration warnings and drug-drug interaction alerts.
- Enterprise GxP Data Fabric — Zero-trust patient sovereignty, hybrid on-premise/VPC deployment, connectors to Veeva Vault, SAP HANA, Medidata Rave, LabWare LIMS, and CDISC SDTM.
Regulatory Compliance
- FDA 21 CFR Part 11 — cryptographically signed audit trails and electronic records
- EU Annex 11 — automated computer system validation in GxP environments
- GAMP 5 Category 5 — custom software lifecycle validation
- ALCOA+ Data Integrity — Attributable, Legible, Contemporaneous, Original, Accurate
- HIPAA & GDPR — zero-trust patient data sovereignty and field-level encryption
ROI Benchmarks
- 10× discovery acceleration — from years to months
- 40% CMC cycle time reduction
- 30–50% faster patient enrollment in clinical trials
- $280B+ pharma R&D addressable market
Contact: hello@aanox.com | Investor Relations